{
    "clinical_study": {
        "@rank": "35073", 
        "arm_group": [
            {
                "arm_group_label": "BOTOX\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "BOTOX\u00ae (onabotulinumtoxinA) injected into the areas of glabellar lines and crow's feet lines on Day 1."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a safety and efficacy study of BOTOX\u00ae in subjects with facial rhytides (glabellar\n      lines and crow's feet lines)."
        }, 
        "brief_title": "A Study of Subject Satisfaction With BOTOX\u00ae Cosmetic Treatment in Facial Rhytides", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "B1", 
                            "description": "BOTOX\u00ae (onabotulinumtoxinA) 44U total dose injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                            "title": "BOTOX\u00ae"
                        }, 
                        {
                            "@group_id": "B2", 
                            "description": "Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                            "title": "Placebo"
                        }, 
                        {
                            "@group_id": "B3", 
                            "description": "Total of all reporting groups", 
                            "title": "Total"
                        }
                    ]
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": [
                                            {
                                                "@group_id": "B1", 
                                                "@value": "60"
                                            }, 
                                            {
                                                "@group_id": "B2", 
                                                "@value": "57"
                                            }, 
                                            {
                                                "@group_id": "B3", 
                                                "@value": "117"
                                            }
                                        ]
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "25"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "24"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "49"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "< 45 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "35"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "33"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "68"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "45 \u2013 65 years"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Age, Customized", 
                            "units": "Participants"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "48"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "50"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "98"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "12"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "7"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "19"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "Participants"
                        }
                    ]
                }, 
                "population": "Baseline measures are based on the Per-Protocol population that included all randomized participants who received study treatment and had at least one post-baseline efficacy assessment and no major protocol deviations."
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "Participants assessed their overall satisfaction with their glabellar (frown) lines using the FLSQ 5-point scale where: -2=Very dissatisfied, -1=Mostly dissatisfied, 0=Neither dissatisfied nor satisfied, 1=Mostly satisfied and 2=Very satisfied. The percentage of participants with responses mostly or very satisfied is reported.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "BOTOX\u00ae (onabotulinumtoxinA) 44U total dose injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                                    "title": "BOTOX\u00ae"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                                    "title": "Placebo"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "60"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "57"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "81.7"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "0.0"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Participants assessed their overall satisfaction with their glabellar (frown) lines using the FLSQ 5-point scale where: -2=Very dissatisfied, -1=Mostly dissatisfied, 0=Neither dissatisfied nor satisfied, 1=Mostly satisfied and 2=Very satisfied. The percentage of participants with responses mostly or very satisfied is reported.", 
                                    "param": "Number", 
                                    "title": "Percentage of Participants Satisfied With Treatment of Glabellar Lines Assessed Using the Facial Line Satisfaction Questionnaire (FLSQ)", 
                                    "units": "Percentage of participants"
                                }
                            ]
                        }, 
                        "population": "Per-Protocol population included all randomized participants who received study treatment and had at least one post-baseline efficacy assessment and no major protocol deviations.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 60", 
                        "title": "Percentage of Participants Satisfied With Treatment of Glabellar Lines Assessed Using the Facial Line Satisfaction Questionnaire (FLSQ)", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Participants assessed their overall satisfaction with both their CFL and glabellar lines using the FLSQ 5-point scale where: -2=Very dissatisfied, -1=Mostly dissatisfied, 0=Neither dissatisfied nor satisfied, 1=Mostly satisfied and 2=Very satisfied. The percentage of participants mostly or very satisfied is reported.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "BOTOX\u00ae (onabotulinumtoxinA) 44U total dose injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                                    "title": "BOTOX\u00ae"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                                    "title": "Placebo"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "60"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "57"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "81.7"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "0.0"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Participants assessed their overall satisfaction with both their CFL and glabellar lines using the FLSQ 5-point scale where: -2=Very dissatisfied, -1=Mostly dissatisfied, 0=Neither dissatisfied nor satisfied, 1=Mostly satisfied and 2=Very satisfied. The percentage of participants mostly or very satisfied is reported.", 
                                    "param": "Number", 
                                    "title": "Percentage of Participants Satisfied With Treatment of Crow\u2019s Feet Lines (CFL) and Glabellar Lines Assessed Using the FLSQ", 
                                    "units": "Percentage of participants"
                                }
                            ]
                        }, 
                        "population": "Per-Protocol population included all randomized participants who received study treatment and had at least one post-baseline efficacy assessment and no major protocol deviations.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 60", 
                        "title": "Percentage of Participants Satisfied With Treatment of Crow\u2019s Feet Lines (CFL) and Glabellar Lines Assessed Using the FLSQ", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Participants assessed their overall satisfaction with duration of treatment of glabellar lines using the FLSQ 5-point scale where: -2=Very dissatisfied, -1=Mostly dissatisfied, 0=Neither dissatisfied nor satisfied, 1=Mostly satisfied and 2=Very satisfied. The percentage of participants with responses mostly or very satisfied is reported.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "BOTOX\u00ae (onabotulinumtoxinA) 44U total dose injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                                    "title": "BOTOX\u00ae"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                                    "title": "Placebo"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "60"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "57"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "65.0"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "0.0"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Participants assessed their overall satisfaction with duration of treatment of glabellar lines using the FLSQ 5-point scale where: -2=Very dissatisfied, -1=Mostly dissatisfied, 0=Neither dissatisfied nor satisfied, 1=Mostly satisfied and 2=Very satisfied. The percentage of participants with responses mostly or very satisfied is reported.", 
                                    "param": "Number", 
                                    "title": "Percentage of Participants Satisfied With Duration of Treatment of Glabellar Lines Assessed Using the FLSQ", 
                                    "units": "Percentage of participants"
                                }
                            ]
                        }, 
                        "population": "Per-Protocol population included all randomized participants who received study treatment and had at least one post-baseline efficacy assessment and no major protocol deviations.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 90", 
                        "title": "Percentage of Participants Satisfied With Duration of Treatment of Glabellar Lines Assessed Using the FLSQ", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Participants assessed whether treatment of their glabellar lines met expectation using the FLSQ 3-point scale where: 1=Worse than expected, 2=Met expectations and 3=Better than expected. The percentage of participants with responses Met expectations and Better than expected is reported.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "BOTOX\u00ae (onabotulinumtoxinA) 44U total dose injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                                    "title": "BOTOX\u00ae"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                                    "title": "Placebo"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "60"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "57"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "88.3"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "14.0"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Participants assessed whether treatment of their glabellar lines met expectation using the FLSQ 3-point scale where: 1=Worse than expected, 2=Met expectations and 3=Better than expected. The percentage of participants with responses Met expectations and Better than expected is reported.", 
                                    "param": "Number", 
                                    "title": "Percentage of Participants Where Treatment of Glabellar Lines Met Expectation Assessed Using the FLSQ", 
                                    "units": "Percentage of participants"
                                }
                            ]
                        }, 
                        "population": "Per-Protocol population included all randomized participants who received study treatment and had at least one post-baseline efficacy assessment and no major protocol deviations.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 60", 
                        "title": "Percentage of Participants Where Treatment of Glabellar Lines Met Expectation Assessed Using the FLSQ", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Participants assessed their overall satisfaction with duration of treatment of both CFL and glabellar lines using the FLSQ 5-point scale where: -2=Very dissatisfied, -1=Mostly dissatisfied, 0=Neither dissatisfied nor satisfied, 1=Mostly satisfied and 2=Very satisfied. The percentage of participants with responses mostly or very satisfied is reported.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "BOTOX\u00ae (onabotulinumtoxinA) 44U total dose injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                                    "title": "BOTOX\u00ae"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                                    "title": "Placebo"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "60"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "57"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "61.7"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "0.0"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Participants assessed their overall satisfaction with duration of treatment of both CFL and glabellar lines using the FLSQ 5-point scale where: -2=Very dissatisfied, -1=Mostly dissatisfied, 0=Neither dissatisfied nor satisfied, 1=Mostly satisfied and 2=Very satisfied. The percentage of participants with responses mostly or very satisfied is reported.", 
                                    "param": "Number", 
                                    "title": "Percentage of Participants Satisfied With Duration of Treatment of CFL and Glabellar Lines Assessed Using the FLSQ", 
                                    "units": "Percentage of participants"
                                }
                            ]
                        }, 
                        "population": "Per-Protocol population included all randomized participants who received study treatment and had at least one post-baseline efficacy assessment and no major protocol deviations.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 90", 
                        "title": "Percentage of Participants Satisfied With Duration of Treatment of CFL and Glabellar Lines Assessed Using the FLSQ", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Participants assessed whether treatment of glabellar lines met expectations using the FLSQ 3-point scale where: 1=Worse than expected, 2=Met expectations and 3=Better than expected. The percentage of participants with responses Met expectations and Better than expected is reported.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "BOTOX\u00ae (onabotulinumtoxinA) 44U total dose injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                                    "title": "BOTOX\u00ae"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                                    "title": "Placebo"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "60"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "57"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "86.7"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "15.8"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Participants assessed whether treatment of glabellar lines met expectations using the FLSQ 3-point scale where: 1=Worse than expected, 2=Met expectations and 3=Better than expected. The percentage of participants with responses Met expectations and Better than expected is reported.", 
                                    "param": "Number", 
                                    "title": "Percentage of Participants Where Treatment of CFL and Glabellar Lines Met Expectation Assessed Using the FLSQ", 
                                    "units": "Percentage of participants"
                                }
                            ]
                        }, 
                        "population": "Per-Protocol population included all randomized participants who received study treatment and had at least one post-baseline efficacy assessment and no major protocol deviations.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 60", 
                        "title": "Percentage of Participants Where Treatment of CFL and Glabellar Lines Met Expectation Assessed Using the FLSQ", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Participants assessed how likely they were to continue treatment of glabellar Lines using the FLSQ 5-point scale where: 1=Not at all, 2=A little bit, 3=Moderately, 4=Quite a bit and 5=Extremely. The percentage of participants with responses Moderately, Quite a bit and Extremely is reported.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "BOTOX\u00ae (onabotulinumtoxinA) 44U total dose injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                                    "title": "BOTOX\u00ae"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                                    "title": "Placebo"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "60"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "57"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "78.3"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "36.8"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Participants assessed how likely they were to continue treatment of glabellar Lines using the FLSQ 5-point scale where: 1=Not at all, 2=A little bit, 3=Moderately, 4=Quite a bit and 5=Extremely. The percentage of participants with responses Moderately, Quite a bit and Extremely is reported.", 
                                    "param": "Number", 
                                    "title": "Percentage of Participants Who Were Likely to Continue Treatment of Glabellar Lines Assessed Using the FLSQ", 
                                    "units": "Percentage of participants"
                                }
                            ]
                        }, 
                        "population": "Per-Protocol population included all randomized participants who received study treatment and had at least one post-baseline efficacy assessment and no major protocol deviations.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 90", 
                        "title": "Percentage of Participants Who Were Likely to Continue Treatment of Glabellar Lines Assessed Using the FLSQ", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Participants assessed how likely they were to continue treatment of CFL and glabellar Lines using the FLSQ 5-point scale where: 1=Not at all, 2=A little bit, 3=Moderately, 4=Quite a bit and 5=Extremely. The percentage of participants with responses Moderately, Quite a bit and Extremely is reported.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "BOTOX\u00ae (onabotulinumtoxinA) 44U total dose injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                                    "title": "BOTOX\u00ae"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                                    "title": "Placebo"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "60"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "57"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "78.3"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "31.6"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Participants assessed how likely they were to continue treatment of CFL and glabellar Lines using the FLSQ 5-point scale where: 1=Not at all, 2=A little bit, 3=Moderately, 4=Quite a bit and 5=Extremely. The percentage of participants with responses Moderately, Quite a bit and Extremely is reported.", 
                                    "param": "Number", 
                                    "title": "Percentage of Participants Who Were Likely to Continue Treatment of CFL and Glabellar Lines Assessed Using the FLSQ", 
                                    "units": "Percentage of participants"
                                }
                            ]
                        }, 
                        "population": "Per-Protocol population included all randomized participants who received study treatment and had at least one post-baseline efficacy assessment and no major protocol deviations.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 90", 
                        "title": "Percentage of Participants Who Were Likely to Continue Treatment of CFL and Glabellar Lines Assessed Using the FLSQ", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "The Investigator assessed the severity of the patient\u2019s glabellar lines at maximum frown using the 4-point Facial Wrinkle Scale (FWS) where: 0=none, 1=mild, 2=moderate, and 3=severe. The percentage of participants with a score of none or mild is reported.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "BOTOX\u00ae (onabotulinumtoxinA) 44U total dose injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                                    "title": "BOTOX\u00ae"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                                    "title": "Placebo"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "60"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "57"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "83.3"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "1.8"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "The Investigator assessed the severity of the patient\u2019s glabellar lines at maximum frown using the 4-point Facial Wrinkle Scale (FWS) where: 0=none, 1=mild, 2=moderate, and 3=severe. The percentage of participants with a score of none or mild is reported.", 
                                    "param": "Number", 
                                    "title": "Percentage of Participants With a Score of None or Mild in the Investigator's Assessment of the Severity of Glabellar Lines at Maximum Frown Assessed Using the FWS", 
                                    "units": "Percentage of participants"
                                }
                            ]
                        }, 
                        "population": "Per-Protocol population included all randomized participants who received study treatment and had at least one post-baseline efficacy assessment and no major protocol deviations.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 30", 
                        "title": "Percentage of Participants With a Score of None or Mild in the Investigator's Assessment of the Severity of Glabellar Lines at Maximum Frown Assessed Using the FWS", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "The Investigator assessed the severity of the patient\u2019s CFL at maximum smile using the 4-point FWS where: 0=none, 1=mild, 2=moderate, and 3=severe. The percentage of participants with at least a 1-Grade improvement from Baseline is reported.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "BOTOX\u00ae (onabotulinumtoxinA) 44U total dose injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                                    "title": "BOTOX\u00ae"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                                    "title": "Placebo"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "60"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "57"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "86.7"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "8.8"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "The Investigator assessed the severity of the patient\u2019s CFL at maximum smile using the 4-point FWS where: 0=none, 1=mild, 2=moderate, and 3=severe. The percentage of participants with at least a 1-Grade improvement from Baseline is reported.", 
                                    "param": "Number", 
                                    "title": "Percentage of Participants With at Least a 1-Grade Improvement in the Investigator's Assessment of the Severity of CFL at Maximum Smile Assessed Using the FWS", 
                                    "units": "Percentage of participants"
                                }
                            ]
                        }, 
                        "population": "Per-Protocol population included all randomized participants who received study treatment and had at least one post-baseline efficacy assessment and no major protocol deviations.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline, Day 30", 
                        "title": "Percentage of Participants With at Least a 1-Grade Improvement in the Investigator's Assessment of the Severity of CFL at Maximum Smile Assessed Using the FWS", 
                        "type": "Secondary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "P1", 
                            "description": "BOTOX\u00ae (onabotulinumtoxinA) 44U total dose injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                            "title": "BOTOX\u00ae"
                        }, 
                        {
                            "@group_id": "P2", 
                            "description": "Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                            "title": "Placebo"
                        }
                    ]
                }, 
                "period_list": {
                    "period": {
                        "drop_withdraw_reason_list": {
                            "drop_withdraw_reason": {
                                "participants_list": {
                                    "participants": [
                                        {
                                            "@count": "1", 
                                            "@group_id": "P1"
                                        }, 
                                        {
                                            "@count": "0", 
                                            "@group_id": "P2"
                                        }
                                    ]
                                }, 
                                "title": "Subject Withdrawal"
                            }
                        }, 
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "63", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "62", 
                                                "@group_id": "P2"
                                            }
                                        ]
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "62", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "62", 
                                                "@group_id": "P2"
                                            }
                                        ]
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "1", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "0", 
                                                "@group_id": "P2"
                                            }
                                        ]
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }
            }, 
            "point_of_contact": {
                "email": "clinicaltrials@allergan.com", 
                "name_or_title": "Vice President  Medical Affairs,", 
                "organization": "Allergan, Inc", 
                "phone": "714-246-4500"
            }, 
            "reported_events": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "E1", 
                            "description": "BOTOX\u00ae (onabotulinumtoxinA) 44U total dose injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                            "title": "BOTOX\u00ae"
                        }, 
                        {
                            "@group_id": "E2", 
                            "description": "Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                            "title": "Placebo"
                        }
                    ]
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "6", 
                                                "@subjects_at_risk": "63"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "4", 
                                                "@subjects_at_risk": "62"
                                            }
                                        ], 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "6", 
                                                "@subjects_at_risk": "63"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "4", 
                                                "@subjects_at_risk": "62"
                                            }
                                        ], 
                                        "sub_title": "Headache"
                                    }
                                }, 
                                "title": "Nervous system disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Non-systematic Assessment", 
                    "default_vocab": "MedDRA 15.1", 
                    "frequency_threshold": "5"
                }, 
                "serious_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "63"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "62"
                                            }
                                        ], 
                                        "sub_title": "Total, serious adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "63"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "62"
                                            }
                                        ], 
                                        "sub_title": "Squamous  cell carcinoma"
                                    }
                                }, 
                                "title": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)"
                            }
                        ]
                    }, 
                    "default_assessment": "Systematic Assessment", 
                    "default_vocab": "MedDRA 15.1"
                }
            }
        }, 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Facial Rhytides", 
        "condition_browse": {
            "mesh_term": "Facies"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Glabellar lines and crow's feet lines\n\n          -  No prior use of botulinum toxin therapy of any serotype for any reason\n\n        Exclusion Criteria:\n\n          -  Previous facial cosmetic surgery, tissue grafting, or tissue augmentation with\n             silicone or fat or other permanent fillers\n\n          -  Planning a facial cosmetic procedure during the study period\n\n          -  Diagnosis of myasthenia gravis, Eaton-Lambert Syndrome, and/or amyotrophic lateral\n             sclerosis\n\n          -  Anticipated need for treatment with botulinum toxin of any serotype for any reason\n             during the study (other than study treatment)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "125", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 25, 2013", 
        "firstreceived_results_date": "May 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01777620", 
            "org_study_id": "GMA-BTXC-12-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "BOTOX\u00ae", 
                "description": "BOTOX\u00ae (onabotulinumtoxinA) injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                "intervention_name": "onabotulinumtoxinA", 
                "intervention_type": "Biological", 
                "other_name": [
                    "botulinum toxin Type A", 
                    "BOTOX\u00ae", 
                    "BOTOX\u00ae Cosmetic"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.", 
                "intervention_name": "Normal Saline", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Toronto", 
                    "country": "Canada", 
                    "state": "Ontario"
                }
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Canada: Ethics Review Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Participants assessed their overall satisfaction with their glabellar (frown) lines using the FLSQ 5-point scale where: -2=Very dissatisfied, -1=Mostly dissatisfied, 0=Neither dissatisfied nor satisfied, 1=Mostly satisfied and 2=Very satisfied. The percentage of participants with responses mostly or very satisfied is reported.", 
            "measure": "Percentage of Participants Satisfied With Treatment of Glabellar Lines Assessed Using the Facial Line Satisfaction Questionnaire (FLSQ)", 
            "safety_issue": "No", 
            "time_frame": "Day 60"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01777620"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Participants assessed their overall satisfaction with both their CFL and glabellar lines using the FLSQ 5-point scale where: -2=Very dissatisfied, -1=Mostly dissatisfied, 0=Neither dissatisfied nor satisfied, 1=Mostly satisfied and 2=Very satisfied. The percentage of participants mostly or very satisfied is reported.", 
                "measure": "Percentage of Participants Satisfied With Treatment of Crow's Feet Lines (CFL) and Glabellar Lines Assessed Using the FLSQ", 
                "safety_issue": "No", 
                "time_frame": "Day 60"
            }, 
            {
                "description": "Participants assessed their overall satisfaction with duration of treatment of glabellar lines using the FLSQ 5-point scale where: -2=Very dissatisfied, -1=Mostly dissatisfied, 0=Neither dissatisfied nor satisfied, 1=Mostly satisfied and 2=Very satisfied. The percentage of participants with responses mostly or very satisfied is reported.", 
                "measure": "Percentage of Participants Satisfied With Duration of Treatment of Glabellar Lines Assessed Using the FLSQ", 
                "safety_issue": "No", 
                "time_frame": "Day 90"
            }, 
            {
                "description": "Participants assessed whether treatment of their glabellar lines met expectation using the FLSQ 3-point scale where: 1=Worse than expected, 2=Met expectations and 3=Better than expected. The percentage of participants with responses Met expectations and Better than expected is reported.", 
                "measure": "Percentage of Participants Where Treatment of Glabellar Lines Met Expectation Assessed Using the FLSQ", 
                "safety_issue": "No", 
                "time_frame": "Day 60"
            }, 
            {
                "description": "Participants assessed their overall satisfaction with duration of treatment of both CFL and glabellar lines using the FLSQ 5-point scale where: -2=Very dissatisfied, -1=Mostly dissatisfied, 0=Neither dissatisfied nor satisfied, 1=Mostly satisfied and 2=Very satisfied. The percentage of participants with responses mostly or very satisfied is reported.", 
                "measure": "Percentage of Participants Satisfied With Duration of Treatment of CFL and Glabellar Lines Assessed Using the FLSQ", 
                "safety_issue": "No", 
                "time_frame": "Day 90"
            }, 
            {
                "description": "Participants assessed whether treatment of glabellar lines met expectations using the FLSQ 3-point scale where: 1=Worse than expected, 2=Met expectations and 3=Better than expected. The percentage of participants with responses Met expectations and Better than expected is reported.", 
                "measure": "Percentage of Participants Where Treatment of CFL and Glabellar Lines Met Expectation Assessed Using the FLSQ", 
                "safety_issue": "No", 
                "time_frame": "Day 60"
            }, 
            {
                "description": "Participants assessed how likely they were to continue treatment of glabellar Lines using the FLSQ 5-point scale where: 1=Not at all, 2=A little bit, 3=Moderately, 4=Quite a bit and 5=Extremely. The percentage of participants with responses Moderately, Quite a bit and Extremely is reported.", 
                "measure": "Percentage of Participants Who Were Likely to Continue Treatment of Glabellar Lines Assessed Using the FLSQ", 
                "safety_issue": "No", 
                "time_frame": "Day 90"
            }, 
            {
                "description": "Participants assessed how likely they were to continue treatment of CFL and glabellar Lines using the FLSQ 5-point scale where: 1=Not at all, 2=A little bit, 3=Moderately, 4=Quite a bit and 5=Extremely. The percentage of participants with responses Moderately, Quite a bit and Extremely is reported.", 
                "measure": "Percentage of Participants Who Were Likely to Continue Treatment of CFL and Glabellar Lines Assessed Using the FLSQ", 
                "safety_issue": "No", 
                "time_frame": "Day 90"
            }, 
            {
                "description": "The Investigator assessed the severity of the patient's glabellar lines at maximum frown using the 4-point Facial Wrinkle Scale (FWS) where: 0=none, 1=mild, 2=moderate, and 3=severe. The percentage of participants with a score of none or mild is reported.", 
                "measure": "Percentage of Participants With a Score of None or Mild in the Investigator's Assessment of the Severity of Glabellar Lines at Maximum Frown Assessed Using the FWS", 
                "safety_issue": "No", 
                "time_frame": "Day 30"
            }, 
            {
                "description": "The Investigator assessed the severity of the patient's CFL at maximum smile using the 4-point FWS where: 0=none, 1=mild, 2=moderate, and 3=severe. The percentage of participants with at least a 1-Grade improvement from Baseline is reported.", 
                "measure": "Percentage of Participants With at Least a 1-Grade Improvement in the Investigator's Assessment of the Severity of CFL at Maximum Smile Assessed Using the FWS", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 30"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}